help button home button
AJRCCM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Fahy, J. V.
Right arrow Articles by Boushey, H. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fahy, J. V.
Right arrow Articles by Boushey, H. A.

Am. J. Respir. Crit. Care Med., Vol 152, No. 3, Sep 1995, 879-884.

Effect of an NK1 receptor antagonist (CP-99,994) on hypertonic saline- induced bronchoconstriction and cough in male asthmatic subjects

JV Fahy, HH Wong, P Geppetti, JM Reis, SC Harris, DB Maclean, JA Nadel and HA Boushey
Department of Medicine, University of California, San Francisco 94143, USA.

To investigate the role of NK1 receptors in the pathogenesis of bronchoconstriction and cough in asthma, we performed a randomized, double-blind, crossover study on the effects of a selective non-peptide tachykinin NK1 receptor antagonist (CP-99,994) on baseline measures of lung function and on hypertonic saline-induced bronchoconstriction and cough in 14 male subjects with mild asthma. CP-99,994 (250 micrograms/2 hours) and placebo were administered intravenously in 2-h infusions during consecutive visits 5 to 7 d apart. Specific airway resistance (SRaw) was measured and spirometry was performed at baseline and at 35 and 60 min. Next, hypertonic saline challenge was performed by delivering 10 breaths of saline of increasing concentration (0.9 to 7% in 1% increments at 5-min intervals) via an ultrasonic nebulizer until SRaw increased from baseline by 200% or 20 units, whichever was greater. Throughout the challenge cough was counted from a taped record made from two microphones placed close to the subject's larynx. We found that CP-99,994 did not significantly affect SRaw or spirometric measures of lung function during the first hour of infusion. Although CP-99,994 infusion markedly attenuated the bronchoconstrictor response to the saline challenge in two subjects, it did not significantly decrease the area under curves obtained for SRaw and cough during saline challenge for the group as a whole (p = 0.9 for SRaw;p = 0.8 for cough). We conclude that administration of 250 micrograms/kg of CP- 99,994 over 2 h does not significantly inhibit hypertonic saline- induced bronchoconstriction or cough in subjects with mild asthma and does not have acute bronchodilator activity in these subjects.


This article has been cited by other articles:


Home page
 Am. J. Respir. Crit. Care Med.Home page
J. D. Boot, S. de Haas, S. Tarasevych, C. Roy, L. Wang, D. Amin, J. Cohen, P. J. Sterk, B. Miller, A. Paccaly, et al.
Effect of an NK1/NK2 Receptor Antagonist on Airway Responses and Inflammation to Allergen in Asthma
Am. J. Respir. Crit. Care Med., March 1, 2007; 175(5): 450 - 457.
[Abstract] [Full Text] [PDF]

Home page
 ThoraxHome page
A H Morice, L McGarvey, I Pavord, and on behalf of the British Thoracic Society Cough Gu
Recommendations for the management of cough in adults
Thorax, September 1, 2006; 61(suppl_1): i1 - i24.
[Full Text] [PDF]

Home page
 ChestHome page
H. O. Koskela, K. M. Kontra, M. K. Purokivi, and J. T. Randell
Interpretation of Cough Provoked by Airway Challenges
Chest, November 1, 2005; 128(5): 3329 - 3335.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
A.H. Morice and committee members
The diagnosis and management of chronic cough
Eur. Respir. J., September 1, 2004; 24(3): 481 - 492.
[Full Text] [PDF]

Home page
 Psychosom. Med.Home page
R. A. Joachim, V. Sagach, D. Quarcoo, Q. T. Dinh, P. C. Arck, and B. F. Klapp
Neurokinin-1 Receptor Mediates Stress-Exacerbated Allergic Airway Inflammation and Airway Hyperresponsiveness in Mice
Psychosom Med, July 1, 2004; 66(4): 564 - 571.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
H. O. Koskela, L. Hyvarinen, J. D. Brannan, H.-K. Chan, and S. D. Anderson
Coughing During Mannitol Challenge Is Associated With Asthma
Chest, June 1, 2004; 125(6): 1985 - 1992.
[Abstract] [Full Text] [PDF]

Home page
 Ann. N. Y. Acad. Sci.Home page
G. F. JOOS, K. O. DE SWERT, V. SCHELFHOUT, and R. A. PAUWELS
The Role of Neural Inflammation in Asthma and Chronic Obstructive Pulmonary Disease
Ann. N.Y. Acad. Sci., May 1, 2003; 992(1): 218 - 230.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
A. N. Freed, S. McCulloch, T. Meyers, and R. Suzuki
Neurokinins Modulate Hyperventilation-induced Bronchoconstriction in Canine Peripheral Airways
Am. J. Respir. Crit. Care Med., April 15, 2003; 167(8): 1102 - 1108.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
A. A. H. P. Megens, D. Ashton, J. C. A. Vermeire, P. C. M. Vermote, K. A. Hens, L. C. Hillen, J. F. Fransen, M. Mahieu, L. Heylen, J. E. Leysen, et al.
Pharmacological Profile of (2R-trans)-4-[1-[3,5-bis(Trifluoromethyl)benzoyl]-2-(phenylmethyl)-4-piperidinyl]-N-(2,6-dimethylphenyl)-1-acetamide (S)-Hydroxybutanedioate (R116301), an Orally and Centrally Active Neurokinin-1 Receptor Antagonist
J. Pharmacol. Exp. Ther., August 1, 2002; 302(2): 696 - 709.
[Abstract] [Full Text] [PDF]

Home page
 Pharmacol. Rev.Home page
P. J. Barnes, K. F. Chung, and C. P. Page
Inflammatory Mediators of Asthma: An Update
Pharmacol. Rev., December 1, 1998; 50(4): 515 - 596.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Proc. Am. Thorac. Soc. Am. J. Respir. Cell Mol. Biol.
Copyright © 1995 American Thoracic Society 		  Solid Organ Transplant for the Intensivist 2008